For research use only. Not for therapeutic Use.
Vunakizumab（Cat No.:I042246）is a monoclonal antibody designed to target interleukin-22 (IL-22), a cytokine involved in inflammation and immune responses. IL-22 plays a role in maintaining the integrity of mucosal barriers and promoting tissue repair, but its dysregulation is associated with inflammatory diseases such as psoriasis and inflammatory bowel disease. By inhibiting IL-22, Vunakizumab aims to reduce excessive inflammation and improve symptoms in patients with these conditions. Ongoing clinical trials are investigating its efficacy, safety, and potential as a treatment option for various inflammatory disorders, especially those related to autoimmune conditions.
| Catalog Number | I042246 |
| CAS Number | 1792181-33-9 |
| Purity | ≥95% |
